Cart
0

Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, and Others), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Others), and Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, and Anti-allergy) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_17310
Pages: 351
Nov 2017 | 6199 Views
 
Author's : Tanvi Sapatnekar & Garima Chandra
Tables: 221
Charts: 46
 

Ophthalmic Drugs Market Overview:

Global Ophthalmic Drugs Market size was valued at $29,613 million in 2016, and is expected to reach $42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023. Ophthalmic drugs are extensively used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders. According to the American Academy of Ophthalmology, 11 million people in the U.S. suffer from age-related macular degeneration (AMD), while approximately 10% of them are inflicted with wet AMD. Such trends in ophthalmic disorders across the globe contribute to the growth of the market.

The other key factors that boost the ophthalmic drug market size include high prevalence of glaucoma worldwide and rise in transition towards development of combination therapies for the treatment of glaucoma. In addition, the dynamics in the demographics across the globe contribute to the market growth. However, risk of side effects associated with ophthalmic drugs and the longer timelines required for novel ophthalmic drugs hamper this growth. Moreover, increase in investment by market players in emerging economies offers lucrative opportunities for market growth in near future.

Indication Segment Review

The ophthalmic drugs industry is segmented based on indication into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. Retinal disorders indication has registered significant growth rate, registering a CAGR of 5.8% from 2017 to 2023. The dry age-related macular degeneration segment accounts for the highest share among all the retinal disorders in 2016, and is expected to continue this trend throughout the forecast period.

Global Ophthalmic Drugs Market Segmentation: By Indication

Get more information on this report : Request Sample Pages

Dosage Form Segment Review

The ophthalmic drugs industry analysis is segmented based on dosage form into liquid, solid, semisolid, multicompartment drug delivery systems, and other ophthalmic drug forms. Liquid ophthalmic drug form segment accounted for the highest revenue in 2016, and is projected to maintain the trend throughout the forecast period. However, multicompartment drug delivery systems registered the highest CAGR of 8.0%. This is attributed to increase in development of novel ocular drug delivery approaches including nanoparticles, noisome, and dendrimers.

Get more information on this report : Request Sample Pages

Based on geography, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America dominates the global market, accounting for 36% of the total market share in 2016, and is anticipated to lead throughout the forecast period. The report provides a comprehensive analysis of the key players operating in the global market such as Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis), Genentech, Inc. Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.

Get more information on this report : Request Sample Pages

The other key players in the value chain include Abbott Medical Optics, Inc., Carl-Zeiss AG, Ellex Medical Lasers Ltd., Essilor International S.A., Hoya Corporation, Insight Vision Inc., Nidek Co.Ltd, Novagali Pharma S A, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

Key Benefits

The study provides an in-depth analysis with the current trends and future estimations of the global ophthalmic drugs market to elucidate the imminent investment pockets.
Comprehensive analysis of the factors that drive and restrict the market growth is provided.
The quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of key segments of the industry is provided to understand the type of ophthalmic drugs used globally.
Key players and their strategies are analyzed to understand the competitive outlook of the market.

Ophthalmic Drugs Market Key Segments:

By Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
    • Wet Age-related Macular Degeneration
    • Dry Age-related Macular Degeneration
    • Diabetic Retinopathy
    • Others
  • Others

By Type

  • Prescription Drugs
  • Over-the-Counter Drugs

By Dosage Form

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms

By Technology

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small molecule
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

By Therapeutic Class

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammatory
  • Anti-allergy

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Turkey
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1    INTRODUCTION

1.1.    REPORT DESCRIPTION
1.2.    KEY BENEFITS
1.3.    KEY MARKET SEGMENTS
1.4.    RESEARCH METHODOLOGY

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools & models

Chapter: 2    EXECUTIVE SUMMARY

2.1.    CXO PERSPECTIVE

Chapter: 3    MARKET OVERVIEW

3.1.    MARKET DEFINITION AND SCOPE
3.2.    KEY FINDINGS

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies

3.3.    PORTER’S FIVE FORCES ANALYSIS
3.4.    MARKET SHARE ANALYSIS, 2016
3.5.    MARKET DYNAMICS

3.5.1.    Drivers

3.5.1.1.    Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders
3.5.1.2.    Rise in prevalence of ophthalmic disorders worldwide
3.5.1.3.    Change in the demographics across the globe

3.5.2.    Restraints

3.5.2.1.    Longer timelines required for the development of ophthalmic drugs
3.5.2.2.    Risk of side effects associated with ophthalmic drugs

3.5.3.    Opportunity

3.5.3.1.    Increase in investment by market players in the emerging economies

Chapter: 4    OPHTHALMIC DRUGS MARKET,  BY INDICATION

4.1.    OVERVIEW

4.1.1.    Market size and forecast

4.2.    DRY EYE

4.2.1.    Key market trends
4.2.2.    Growth factors and opportunities
4.2.3.    Market size and forecast
4.2.4.    North America Market size and forecast, by country
4.2.5.    Europe Market size and forecast, by country
4.2.6.    Asia-Pacific Market size and forecast, by country
4.2.7.    LAMEA Market size and forecast, by country

4.3.    GLAUCOMA

4.3.1.    Key market trends
4.3.2.    Growth factors and opportunities
4.3.3.    Market size and forecast
4.3.4.    North America Market size and forecast, by country
4.3.5.    Europe Market size and forecast, by country
4.3.6.    Asia-Pacific Market size and forecast, by country
4.3.7.    LAMEA Market size and forecast, by country

4.4.    INFECTION/INFLAMMATION/ALLERGY

4.4.1.    Key market trends
4.4.2.    Growth factors and opportunities
4.4.3.    Market size and forecast
4.4.4.    North America Market size and forecast, by country
4.4.5.    Europe Market size and forecast, by country
4.4.6.    Asia-Pacific Market size and forecast, by country
4.4.7.    LAMEA Market size and forecast, by country

4.5.    RETINAL DISORDERS

4.5.1.    Key market trends
4.5.2.    Growth factors and opportunities
4.5.3.    Market size and forecast
4.5.4.    Wet age-related macular degeneration

4.5.4.1.    Market size and forecast

4.5.5.    Dry age-related macular degeneration

4.5.5.1.    Market size and forecast

4.5.6.    Diabetic retinopathy

4.5.6.1.    Market size and forecast

4.5.7.    Others

4.5.7.1.    Market size and forecast

4.6.    OTHERS

4.6.1.    Key market trends
4.6.2.    Growth factors and opportunities
4.6.3.    Market size and forecast

Chapter: 5    OPHTHALMIC DRUGS MARKET,  BY TYPE

5.1.    OVERVIEW

5.1.1.    Market size and forecast

5.2.    PRESCRIPTION DRUGS

5.2.1.    Market size and forecast

5.3.    OVER-THE-COUNTER DRUGS

5.3.1.    Market size and forecast

Chapter: 6    OPHTHALMIC DRUGS MARKET,  BY DISTRIBUTION CHANNEL

6.1.    OVERVIEW

6.1.1.    Market size and forecast

6.2.    HOSPITAL PHARMACIES

6.2.1.    Market size and forecast

6.3.    DRUG STORES

6.3.1.    Market size and forecast

6.4.    ONLINE PHARMACIES

6.4.1.    Market size and forecast

6.5.    OTHERS

6.5.1.    Market size and forecast

Chapter: 7    OPHTHALMIC DRUGS MARKET,  BY DOSAGE FORM

7.1.    OVERVIEW

7.1.1.    Market size and forecast

7.2.    LIQUID OPHTHALMIC DRUG FORMS

7.2.1.    Market size and forecast

7.3.    SEMISOLID OPHTHALMIC DRUG FORMS

7.3.1.    Market size and forecast

7.4.    SOLID OPHTHALMIC DRUG FORMS

7.4.1.    Market size and forecast

7.5.    MULTICOMPARTMENT DRUG DELIVERY SYSTEMS

7.5.1.    Market size and forecast

7.6.    OTHER OPHTHALMIC DRUG FORMS

7.6.1.    Market size and forecast

Chapter: 8    OPHTHALMIC DRUGS MARKET,  BY THERAPEUTIC CLASS

8.1.    OVERVIEW

8.1.1.    Market size and forecast

8.2.    ANTI-INFLAMMATORY

8.2.1.    Market size and forecast
8.2.2.    Nonsteroidal anti-inflammatory drugs (NSAIDs)
8.2.3.    Steroids

8.3.    ANTI-INFECTIVE

8.3.1.    Market size and forecast
8.3.2.    Antifungal drugs
8.3.3.    Antibacterial drugs
8.3.4.    Others

8.4.    ANTI-GLAUCOMA

8.4.1.    Market size and forecast
8.4.2.    Beta blockers
8.4.3.    Prostaglandin analogs
8.4.4.    Others

8.5.    ANTI-ALLERGY

8.5.1.    Market size and forecast

Chapter: 9    OPHTHALMIC DRUGS MARKET,  BY TECHNOLOGY

9.1.    OVERVIEW

9.1.1.    Market size and forecast

9.2.    BIOLOGICS

9.2.1.    Market size and forecast

9.3.    CELL THERAPY

9.3.1.    Market size and forecast

9.4.    GENE THERAPY

9.4.1.    Market size and forecast

9.5.    SMALL MOLECULE

9.5.1.    Market size and forecast

9.6.    DRUG DELIVERY

9.6.1.    Market size and forecast

9.7.    OTHERS

9.7.1.    Market size and forecast

Chapter: 10    OPHTHALMIC DRUGS MARKET,  BY REGION

10.1.    OVERVIEW

10.1.1.    Market size and forecast

10.2.    NORTH AMERICA

10.2.1.    Key market trends
10.2.2.    Key growth factors and opportunities
10.2.3.    Market size and forecast, by country
10.2.4.    Market size and forecast, by indication
10.2.5.    Market size and forecast, by type
10.2.6.    Market size and forecast, by technology
10.2.7.    Market size and forecast, by distribution channel
10.2.8.    Market size and forecast, by dosage form
10.2.9.    Market size and forecast, by therapeutic class

10.2.9.1.    U.S., by indication
10.2.9.2.    U.S., by type
10.2.9.3.    U.S., by distribution channel
10.2.9.4.    U.S., by dosage form
10.2.9.5.    U.S., by technology
10.2.9.6.    U.S., by therapeutic class
10.2.9.7.    Canada, by indication
10.2.9.8.    Canada, by type
10.2.9.9.    Canada, by distribution channel
10.2.9.10.    Canada, by dosage form
10.2.9.11.    Canada, by technology
10.2.9.12.    Canada, by therapeutic class
10.2.9.13.    Mexico, by indication
10.2.9.14.    Mexico, by type
10.2.9.15.    Mexico, by distribution channel
10.2.9.16.    Mexico, by dosage form
10.2.9.17.    Mexico, by technology
10.2.9.18.    Mexico, by therapeutic class

10.3.    EUROPE

10.3.1.    Key market trends
10.3.2.    Key growth factors and opportunities
10.3.3.    Europe Market size and forecast, by country
10.3.4.    Market size and forecast, by indication
10.3.5.    Market size and forecast, by type
10.3.6.    Market size and forecast, by technology
10.3.7.    Market size and forecast, by distribution channel
10.3.8.    Market size and forecast, by dosage form
10.3.9.    Market size and forecast, by therapeutic class

10.3.9.1.    Germany, by indication
10.3.9.2.    Germany, by type
10.3.9.3.    Germany, by distribution channel
10.3.9.4.    Germany, by dosage form
10.3.9.5.    Germany, by technology
10.3.9.6.    Germany, by therapeutic class
10.3.9.7.    France, by indication
10.3.9.8.    France, by type
10.3.9.9.    France, by distribution channel
10.3.9.10.    France, by dosage form
10.3.9.11.    France, by technology
10.3.9.12.    France, by therapeutic class
10.3.9.13.    UK, by indication
10.3.9.14.    UK, by type
10.3.9.15.    UK, by distribution channel
10.3.9.16.    UK, by dosage form
10.3.9.17.    UK, by technology
10.3.9.18.    UK, by therapeutic class
10.3.9.19.    Italy, by indication
10.3.9.20.    Italy, by type
10.3.9.21.    Italy, by distribution channel
10.3.9.22.    Italy, by dosage form
10.3.9.23.    Italy, by technology
10.3.9.24.    Italy, by therapeutic class
10.3.9.25.    Spain, by indication
10.3.9.26.    Spain, by type
10.3.9.27.    Spain, by distribution channel
10.3.9.28.    Spain, by dosage form
10.3.9.29.    Spain, by technology
10.3.9.30.    Spain, by therapeutic class
10.3.9.31.    Rest of Europe, by indication
10.3.9.32.    Rest of Europe, by type
10.3.9.33.    Rest of Europe, by distribution channel
10.3.9.34.    Rest of Europe, by dosage form
10.3.9.35.    Rest of Europe, by technology
10.3.9.36.    Rest of Europe, by therapeutic class

10.4.    ASIA-PACIFIC

10.4.1.    Key market trends
10.4.2.    Key growth factors and opportunities
10.4.3.    Asia-Pacific Market size and forecast, by country
10.4.4.    Market size and forecast, by indication
10.4.5.    Market size and forecast, by type
10.4.6.    Market size and forecast, by technology
10.4.7.    Market size and forecast, by distribution channel
10.4.8.    Market size and forecast, by dosage form
10.4.9.    Market size and forecast, by therapeutic class
10.4.9.1.    Japan, by indication
10.4.9.2.    Japan, by type
10.4.9.3.    Japan, by distribution channel
10.4.9.4.    Japan, by dosage form
10.4.9.5.    Japan, by technology
10.4.9.6.    Japan, by therapeutic class
10.4.9.7.    China, by indication
10.4.9.8.    China, by type
10.4.9.9.    China, by distribution channel
10.4.9.10.    China, by dosage form
10.4.9.11.    China, by technology
10.4.9.12.    China, by therapeutic class
10.4.9.13.    India, by indication
10.4.9.14.    India, by type
10.4.9.15.    India, by distribution channel
10.4.9.16.    India, by dosage form
10.4.9.17.    India, by technology
10.4.9.18.    India, by therapeutic class
10.4.9.19.    Australia, by indication
10.4.9.20.    Australia, by type
10.4.9.21.    Australia, by distribution channel
10.4.9.22.    Australia, by dosage form
10.4.9.23.    Australia, by technology
10.4.9.24.    Australia, by therapeutic class
10.4.9.25.    South Korea, by indication
10.4.9.26.    South Korea, by type
10.4.9.27.    South Korea, by distribution channel
10.4.9.28.    South Korea, by dosage form
10.4.9.29.    South Korea, by technology
10.4.9.30.    South Korea, by therapeutic class
10.4.9.31.    Rest of Asia-Pacific, by indication
10.4.9.32.    Rest of Asia-Pacific, by type
10.4.9.33.    Rest of Asia-Pacific, by distribution channel
10.4.9.34.    Rest of Asia-Pacific, by dosage form
10.4.9.35.    Rest of Asia-Pacific, by technology
10.4.9.36.    Rest of Asia-Pacific, by therapeutic class

10.5.    LAMEA

10.5.1.    Key market trends
10.5.2.    Key growth factors and opportunities
10.5.3.    LAMEA Market size and forecast, by country
10.5.4.    Market size and forecast, by indication
10.5.5.    Market size and forecast, by type
10.5.6.    Market size and forecast, by technology
10.5.7.    Market size and forecast, by distribution channel
10.5.8.    Market size and forecast, by dosage form
10.5.9.    Market size and forecast, by therapeutic class

10.5.9.1.    Brazil, by indication
10.5.9.2.    Brazil, by type
10.5.9.3.    Brazil, by distribution channel
10.5.9.4.    Brazil, by dosage form
10.5.9.5.    Brazil, by technology
10.5.9.6.    Brazil, by therapeutic class
10.5.9.7.    South Africa, by indication
10.5.9.8.    South Africa, by type
10.5.9.9.    South Africa, by distribution channel
10.5.9.10.    South Africa, by dosage form
10.5.9.11.    South Africa, by technology
10.5.9.12.    South Africa, by therapeutic class
10.5.9.13.    Turkey, by indication
10.5.9.14.    Turkey, by type
10.5.9.15.    Turkey, by distribution channel
10.5.9.16.    Turkey, by dosage form
10.5.9.17.    Turkey, by technology
10.5.9.18.    Turkey, by therapeutic class
10.5.9.19.    Saudi Arabia, by indication
10.5.9.20.    Saudi Arabia, by type
10.5.9.21.    Saudi Arabia, by distribution channel
10.5.9.22.    Saudi Arabia, by dosage form
10.5.9.23.    Saudi Arabia, by technology
10.5.9.24.    Saudi Arabia, by therapeutic class
10.5.9.25.    Rest of LAMEA, by indication
10.5.9.26.    Rest of LAMEA, by type
10.5.9.27.    Rest of LAMEA, by distribution channel
10.5.9.28.    Rest of LAMEA, by dosage form
10.5.9.29.    Rest of LAMEA, by technology
10.5.9.30.    Rest of LAMEA, by therapeutic class

Chapter: 11    COMPANY PROFILES

11.1.    ALLERGAN PLC

11.1.1.    Company overview
11.1.2.    Company snapshot
11.1.3.    Operating business segments
11.1.4.    Product portfolio
11.1.5.    Business performance
11.1.6.    Key strategic moves and developments

11.2.    F. HOFFMANN-LA ROCHE AG (GENENTECH, INC.)

11.2.1.    Company overview
11.2.2.    Company snapshot
11.2.3.    Operating business segments
11.2.4.    Product portfolio
11.2.5.    Business performance
11.2.6.    Key strategic moves and developments

11.3.    NOVARTIS AG (ALCON-A DIVISION OF NOVARTIS)

11.3.1.    Company overview
11.3.2.    Company snapshot
11.3.3.    Operating business segments
11.3.4.    Product portfolio
11.3.5.    Business performance
11.3.6.    Key strategic moves and developments

11.4.    PFIZER INC.

11.4.1.    Company overview
11.4.2.    Company snapshot
11.4.3.    Operating business segments
11.4.4.    Product portfolio
11.4.5.    Business performance
11.4.6.    Key strategic moves and developments

11.5.    REGENERON PHARMACEUTICALS INC.

11.5.1.    Company overview
11.5.2.    Company snapshot
11.5.3.    Operating business segments
11.5.4.    Product portfolio
11.5.5.    Business performance
11.5.6.    Key strategic moves and developments

11.6.    SANTEN PHARMACEUTICAL CO., LTD.

11.6.1.    Company overview
11.6.2.    Company snapshot
11.6.3.    Operating business segments
11.6.4.    Product portfolio
11.6.5.    Business performance
11.6.6.    Key strategic moves and developments

11.7.    SHIRE PLC

11.7.1.    Company overview
11.7.2.    Company snapshot
11.7.3.    Operating business segments
11.7.4.    Product portfolio
11.7.5.    Business performance
11.7.6.    Key strategic moves and developments

11.8.    SUN PHARMACEUTICAL INDUSTRIES LIMITED

11.8.1.    Company overview
11.8.2.    Company snapshot
11.8.3.    Operating business segments
11.8.4.    Product portfolio
11.8.5.    Business performance
11.8.6.    Key strategic moves and developments

11.9.    TEVA PHARMACEUTICAL INDUSTRIES LTD.( ACTAVIS GENERICS)

11.9.1.    Company overview
11.9.2.    Company snapshot
11.9.3.    Operating business segments
11.9.4.    Product portfolio
11.9.5.    Business performance
11.9.6.    Key strategic moves and developments

11.10.    VALEANT PHARMACEUTICAL INTERNATIONAL, INC. (BAUSCH & LOMB INC.)

11.10.1.    Company overview
11.10.2.    Company snapshot
11.10.3.    Operating business segments
11.10.4.    Product portfolio
11.10.5.    Business performance
11.10.6.    Key strategic moves and developments

LIST OF TABLES

TABLE 1.    NOVARTIS OPHTHALMOLOGIC PIPELINE PORTFOLIO, JULY 2011
TABLE 2.    GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 3.    OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2016–2023 ($MILLION)
TABLE 4.    NORTH AMERICA DRY EYE MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 5.    EUROPE DRY EYE MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 6.    ASIA-PACIFIC DRY EYE MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 7.    LAMEA DRY EYE MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 8.    OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2016–2023 ($MILLION)
TABLE 9.    NORTH AMERICA GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 10.    EUROPE GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 11.    ASIA-PACIFIC GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 12.    LAMEA GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 13.    OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY,  BY REGION, 2016–2023 ($MILLION)
TABLE 14.    NORTH AMERICA GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 15.    EUROPE GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 16.    ASIA-PACIFIC GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 17.    LAMEA GLAUCOMA MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 18.    OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION,  2016–2023 ($MILLION)
TABLE 19.    OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2016–2023 ($MILLION)
TABLE 20.    OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016–2023 ($MILLION)
TABLE 21.    OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016–2023 ($MILLION)
TABLE 22.    OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2016–2023 ($MILLION)
TABLE 23.    OPHTHALMIC DRUGS MARKET FOR OTHER, BY REGION, 2016–2023 ($MILLION)
TABLE 24.    OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016–2023 ($MILLION)
TABLE 25.    GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 26.    PRESCRIPTION OPHTHALMIC DRUGS OFFERED BY BAUSCH + LOMB
TABLE 27.    PRESCRIPTION OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 28.    OPHTHALMIC DRUGS AVAILABLE OVER THE COUNTER FOR THE TREATMENT OF DRY EYE
TABLE 29.    OVER-THE-COUNTER OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 30.    GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL,  2016–2023 ($MILLION)
TABLE 31.    OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION,  2016–2023 ($MILLION)
TABLE 32.    OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2016–2023 ($MILLION)
TABLE 33.    OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2016–2023 ($MILLION)
TABLE 34.    OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016–2023 ($MILLION)
TABLE 35.    GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 36.    OPHTHALMIC DRUGS ADMINISTERED IN LIQUID FORMS
TABLE 37.    LIQUID OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 38.    OPHTHALMIC DRUGS ADMINISTERED IN SEMISOLID FORMS
TABLE 39.    SEMISOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 40.    VARIOUS TYPES OF SOLID OPHTHALMIC DRUG FORMS
TABLE 41.    SOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 42.    MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET, BY REGION,  2016–2023 ($MILLION)
TABLE 43.    OTHER OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 44.    GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 45.    OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY REGION,  2016–2023 ($MILLION)
TABLE 46.    OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTIVE, BY REGION, 2016–2023 ($MILLION)
TABLE 47.    OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY REGION, 2016–2023 ($MILLION)
TABLE 48.    OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY REGION, 2016–2023 ($MILLION)
TABLE 49.    GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 50.    FDA-APPROVED OCULAR BIOLOGICS
TABLE 51.    OPHTHALMIC DRUGS MARKET FOR BIOLOGICS, BY REGION, 2016–2023 ($MILLION)
TABLE 52.    OPHTHALMIC DRUGS MARKET FOR CELL THERAPY, BY REGION, 2016–2023 ($MILLION)
TABLE 53.    OPHTHALMIC DRUGS MARKET FOR GENE THERAPY, BY REGION, 2016–2023 ($MILLION)
TABLE 54.    OPHTHALMIC DRUGS MARKET FOR SMALL MOLECULE, BY REGION, 2016–2023 ($MILLION)
TABLE 55.    OPHTHALMIC DRUGS MARKET FOR DRUG DELIVERY, BY REGION, 2016–2023 ($MILLION)
TABLE 56.    OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016–2023 ($MILLION)
TABLE 57.    OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023 ($MILLION)
TABLE 58.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 59.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 60.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 61.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 62.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 63.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 64.    NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 65.    U.S. OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 66.    U.S. OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 67.    U.S. OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 68.    U.S. OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 69.    U.S. OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 70.    U.S. OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 71.    CANADA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 72.    CANADA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 73.    CANADA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 74.    CANADA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 75.    CANADA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 76.    CANADA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 77.    MEXICO OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 78.    MEXICO OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 79.    MEXICO OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 80.    MEXICO OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 81.    MEXICO OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 82.    MEXICO OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 83.    EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 84.    EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 85.    EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 86.    EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 87.    EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 88.    EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 89.    EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 90.    GERMANY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 91.    GERMANY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 92.    GERMANY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 93.    GERMANY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 94.    GERMANY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 95.    GERMANY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 96.    FRANCE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 97.    FRANCE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 98.    FRANCE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 99.    FRANCE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 100.    FRANCE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 101.    FRANCE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 102.    UK OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 103.    UK OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 104.    UK OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 105.    UK OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 106.    UK OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 107.    UK OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 108.    ITALY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 109.    ITALY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 110.    ITALY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 111.    ITALY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 112.    ITALY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 113.    ITALY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 114.    SPAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 115.    SPAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 116.    SPAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 117.    SPAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 118.    SPAIN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 119.    SPAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 120.    REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 121.    REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 122.    REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 123.    REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 124.    REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 125.    REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 126.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 127.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 128.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 129.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 130.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 131.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 132.    ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS,  2016–2023 ($MILLION)
TABLE 133.    JAPAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 134.    JAPAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 135.    JAPAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 136.    JAPAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 137.    JAPAN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 138.    JAPAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 139.    CHINA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 140.    CHINA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 141.    CHINA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL,  2016–2023 ($MILLION)
TABLE 142.    CHINA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 143.    CHINA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 144.    CHINA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 145.    INDIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 146.    INDIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 147.    INDIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 148.    INDIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 149.    INDIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 150.    INDIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 151.    AUSTRALIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 152.    AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 153.    AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 154.    AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 155.    AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 156.    AUSTRALIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS,  2016–2023 ($MILLION)
TABLE 157.    SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 158.    SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 159.    SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 160.    SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 161.    SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 162.    SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS,  2016–2023 ($MILLION)
TABLE 163.    REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION,  2016–2023 ($MILLION)
TABLE 164.    REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 165.    REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 166.    REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 167.    REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 168.    REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 169.    LAMEA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016–2023 ($MILLION)
TABLE 170.    LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 171.    LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 172.    LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 173.    LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 174.    LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 175.    LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 176.    BRAZIL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 177.    BRAZIL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 178.    BRAZIL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 179.    BRAZIL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 180.    BRAZIL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 181.    BRAZIL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 182.    SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 183.    SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 184.    SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 185.    SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 186.    SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 187.    SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 188.    TURKEY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 189.    TURKEY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 190.    TURKEY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL,  2016–2023 ($MILLION)
TABLE 191.    TURKEY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 192.    TURKEY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 193.    TURKEY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 194.    SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 195.    SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 196.    SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 197.    SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 198.    SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 199.    SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 200.    REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016–2023 ($MILLION)
TABLE 201.    REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016–2023 ($MILLION)
TABLE 202.    REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016–2023 ($MILLION)
TABLE 203.    REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016–2023 ($MILLION)
TABLE 204.    REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016–2023 ($MILLION)
TABLE 205.    REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016–2023 ($MILLION)
TABLE 206.    ALLERGAN: COMPANY SNAPSHOT
TABLE 207.    ALLERGEN: OPERATING SEGMENTS
TABLE 208.    ALLERGAN: PRODUCT PORTFOLIO
TABLE 209.    ROCHE: COMPANY SNAPSHOT
TABLE 210.    ROCHE: OPERATING SEGMENT
TABLE 211.    ROCHE: PRODUCT PORTFOLIO
TABLE 212.    NOVARTIS: COMPANY SNAPSHOT
TABLE 213.    NOVARTIS: OPERATING SEGMENTS
TABLE 214.    NOVARTIS: PRODUCT PORTFOLIO
TABLE 215.    PFIZER: COMPANY SNAPSHOT
TABLE 216.    PFIZER: OPERATING SEGMENTS
TABLE 217.    PFIZER: PRODUCT PORTFOLIO
TABLE 218.    REGENERON: COMPANY SNAPSHOT
TABLE 219.    REGENERON: PRODUCT PORTFOLIO
TABLE 220.    SANTEN PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 221.    SANTEN PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 222.    SANTEN PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 223.    SHIRE: COMPANY SNAPSHOT
TABLE 224.    SHIRE: PRODUCT PORTFOLIO
TABLE 225.    SUN PHARMA: COMPANY SNAPSHOT
TABLE 226.    SUN PHARMA: OPERATING SEGMENTS
TABLE 227.    SUN PHARMA: PRODUCT PORTFOLIO
TABLE 228.    TEVA: COMPANY SNAPSHOT
TABLE 229.    TEVA: OPERATING SEGMENTS
TABLE 230.    TEVA: PRODUCT PORTFOLIO
TABLE 231.    VALEANT: COMPANY SNAPSHOT
TABLE 232.    VALEANT: OPERATING SEGMENTS
TABLE 233.    VALEANT: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1.    GLOBAL OPHTHALMIC DRUGS MARKET SNAPSHOT, 2016–2023
FIGURE 2.    OPHTHALMIC DRUGS MARKET, BY REGION, 2016–2023
FIGURE 3.    MARKET SEGMENTATION
FIGURE 4.    TOP INVESTMENT POCKETS
FIGURE 5.    TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014–2016)
FIGURE 6.    TOTAL NUMBER OF STRATEGIES
FIGURE 7.    TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 8.    HIGH BARGAINING POWER OF BUYERS
FIGURE 9.    MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.    HIGH THREAT OF NEW ENTRANTS
FIGURE 11.    HIGH THREAT OF SUBSTITUTION
FIGURE 12.    MODERATE COMPETITIVE RIVALRY
FIGURE 13.    MARKET SHARE ANALYSIS, 2016
FIGURE 14.    DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 15.    PREVALENT CASES OF AMD IN THE U.S., 2010
FIGURE 16.    GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016
FIGURE 17.    ALLERGAN: NET SALES, 2014–2016 ($MILLION)
FIGURE 18.    ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 19.    ROCHE: NET-SALES, 2014–2016 ($MILLION)
FIGURE 20.    ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21.    ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22.    NOVARTIS: NET SALES, 2014-2016 ($MILLION)
FIGURE 23.    NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24.    NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25.    ALCON: NET SALES, 2014–2016 ($MILLION)
FIGURE 26.    ALCON: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27.    PFIZER: NET SALES, 2014–2016 ($MILLION)
FIGURE 28.    PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 29.    PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 30.    REGENERON: NET SALES, 2014–2016 ($MILLION)
FIGURE 31.    SANTEN PHARMACEUTICAL: NET SALES, 2015–2017 ($MILLION)
FIGURE 32.    SANTEN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33.    SANTEN PHARMACEUTICAL: REVENUE SHARE BY PRODUCT CATEGORY,  2017 (%)
FIGURE 34.    SANTEN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017(%)
FIGURE 35.    SHIRE: NET SALES, 2014–2016 ($MILLION)
FIGURE 36.    SHIRE: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)
FIGURE 37.    SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38.    SUN PHARMA: NET SALES, 2015–2017 ($MILLION)
FIGURE 39.    SUN PHARMA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40.    SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41.    TEVA: NET SALES, 2014–2016 ($MILLION)
FIGURE 42.    TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 43.    TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 44.    VALEANT: NET SALES, 2014–2016 ($MILLION)
FIGURE 45.    VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 46.    VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

 

 

Ophthalmic therapeutic treatment is gaining traction, owing to the increase in number of people suffering from eye ailments, such as eye infections, allergies, and dry eye, each year throughout the world. Thus, significant increase in incidence of glaucoma, cataract, and retinal disorders drives the market growth. In addition, the need for ocular drugs used in the treatment of diabetic retinopathy has increased exponentially, owing to a major proportion of individuals suffering from diabetes.

Prescription ophthalmic drugs accounted the highest revenue in 2016, and are anticipated to lead throughout the forecast period. Small molecule technology for developing ophthalmic drugs dominated the market in 2016, and is set to continue the trend throughout the forecast period. Moreover, ophthalmic disorders are preferably treated by medications administered through topical or systemic route. Topical applications of ophthalmic drugs are incorporated in the treatment of patients suffering from eye ailments, owing to the ease of administration via topical ocular drugs, low cost, and patient compliance. Increase in focus on developing combination therapies for treatment of ophthalmic disorders, prevalence of ophthalmic disorders, and rise in geriatric population are anticipated to drive the growth of the ophthalmic drugs market. However, longer timelines required for the approval of novel ophthalmic drugs and side effects associated with these hamper the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Ophthalmic Drugs Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo